Trial reportBMJ (Clinical research ed.)2023
Implementation of a high sensitivity cardiac troponin I assay and risk of myocardial infarction or death at five years: observational analysis of a stepped wedge, cluster randomised controlled trial.
Trial report in BMJ (Clinical research ed.), 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT01852123 (High-Sensitivity Troponin in the Evaluation of Patients With Acute Coronary Syndrome), which is not on this map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
High-Sensitivity Troponin in the Evaluation of Patients With Acute Coronary Syndrome: A Randomized Controlled Trial
Who cites it
11 citing papers in PubMed, 15 citations in OpenAlex.
- Article
- Introduction of High-Sensitivity Troponin Assay to Rural Tertiary Care Medical Center: Impact on Subsequent Cardiac Diagnostic Testing.Diagnostics (Basel, Switzerland) · 2026Article
- Circulating CD38 shows stronger association with incident heart failure in women despite lower levels: sex differences and kidney-function context.Biology of sex differences · 2026Article
- Development of a High-Sensitivity Electrochemical Immunoassay Using a Fully 3D-Printed Electrocatalytic Microelectrode Probe Platform.Analytical chemistry · 2026Article
- Assessing long-term temporal changes in myocardial infarction treatment and outcomes: chances and challenges.The Lancet regional health. Europe · 2025Article
- Risk Stratification of Acute Chest Pain in Patients With High-Sensitivity Troponin T Below the 99th Percentile: A Long-Term Cohort Study Assessing the Incremental Value of Necrosis and Non-necrosis Biomarkers to Clinical Risk Scores.Journal of the American Heart Association · 2025Observational
- Serial high-sensitivity cardiac troponin I trajectories predict cardiovascular events in hemodialysis patients.Clinical kidney journal · 2025Article
- Cardiac troponin at the point of care in acute and chronic coronary syndromes.Diabetes, obesity & metabolism · 2025Review
- Type 2 myocardial infarction: challenges in diagnosis and treatment.European heart journal · 2025Review
- Diagnostic Value of Long Non-Coding RNA NORAD in Acute Coronary Syndrome: A Diagnostic Biomarker Study.Journal of inflammation research · 2025Article
- Adoption of high-sensitivity cardiac troponin for risk stratification of patients with suspected myocardial infarction: a multicentre cohort study.The Lancet regional health. Europe · 2024Article
Corrections and comments
- Commented on by
- Commented on by
Authors and funding
18 authors at 2 institutions in 1 country.
Funding
Abstract
objectiveTo evaluate the impact of implementing a high sensitivity assay for cardiac troponin I on long term outcomes in patients with suspected acute coronary syndrome.
designSecondary observational analysis of a stepped wedge, cluster randomised controlled trial.
setting10 secondary and tertiary care centres in Scotland, UK.
participants48 282 consecutive patients with suspected acute coronary syndrome. Myocardial injury was defined as any high sensitivity assay result for cardiac troponin I >99th centile of 16 ng/L in women and 34 ng/L in men.
interventionHospital sites were randomly allocated to either early (n=5 hospitals) or late (n=5 hospitals) implementation of a high sensitivity cardiac troponin I assay with sex specific diagnostic thresholds.
main outcome measureThe main outcome was myocardial infarction or death at five years.
results10 360 patients had cardiac troponin concentrations greater than the 99th centile, of whom 1771 (17.1%) were reclassified by the high sensitivity assay. The five year incidence of subsequent myocardial infarction or death before and after implementation of the high sensitivity assay was 29.4% (5588/18 978)
conclusionsImplementation of a high sensitivity cardiac troponin I assay in the assessment of patients with suspected acute coronary syndrome was associated with a reduced risk of subsequent myocardial infarction or death at five years in those reclassified by the high sensitivity assay. Improvements in outcome were greatest in patients with non-ischaemic myocardial injury, suggesting a broader benefit beyond the identification of myocardial infarction.
trial registrationClinicalTrials.gov NCT01852123.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.